Giuseppe Capri

机构：Fondazione IRCCS Istituto Nazionale dei Tumori · ORCID：0000-0003-4260-0349

发表论文 123 篇 · 总被引 3818 次 · h-index 31

代表论文

• The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab (2021 · Cancers · 被引 111)
• Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study (2025 · Annals of Oncology · 被引 44)
• Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study (2020 · Annals of Surgery · 被引 43)
• Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management (2020 · Breast Cancer Research and Treatment · 被引 38)
• Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients (2024 · Cell Metabolism · 被引 29)
• The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis (2023 · Therapeutic Advances in Medical Oncology · 被引 26)